Last updated: July 31, 2026
Humate-P is a plasma-derived von Willebrand factor/factor VIII concentrate marketed by CSL Behring for von Willebrand disease and hemophilia A. Its core FDA approvals are mature, and no new pivotal clinical program is publicly driving the product. Humate-P remains commercially relevant because it is established, licensed for surgical and bleeding indications, and supported by manufacturing scale. Its main risks are competition from recombinant von Willebrand factor, other plasma-derived concentrates, expanded prophylaxis options and hospital purchasing pressure.
What is Humate-P and what does it treat?
Humate-P contains human von Willebrand factor and coagulation factor VIII derived from pooled human plasma. The product is administered intravenously.
The FDA label covers:
- Treatment and prevention of bleeding in adults and pediatric patients with von Willebrand disease.
- Perioperative management of bleeding in patients with von Willebrand disease.
- On-demand treatment and control of bleeding episodes in adults with hemophilia A.
- Perioperative management of bleeding in adults with hemophilia A.
Humate-P is not approved for routine prophylaxis in hemophilia A. Its VWD use is broader than its hemophilia A use because the product supplies both VWF and FVIII, while the primary therapeutic need in VWD is restoration of deficient or defective VWF activity.
What is the active ingredient in Humate-P?
Humate-P is a combined VWF/FVIII biologic. The label expresses potency in international units of VWF ristocetin cofactor activity and factor VIII activity. Its VWF multimers are derived from human plasma and are important for platelet adhesion and stabilization of endogenous factor VIII.
How is Humate-P different from recombinant VWF?
The principal distinction is source and composition:
| Attribute |
Humate-P |
Vonvendi |
| Manufacturer |
CSL Behring |
Takeda |
| Source |
Plasma-derived |
Recombinant VWF |
| FVIII content |
Present |
Primarily VWF; FVIII may be co-administered initially |
| FDA approval |
VWD and hemophilia A |
VWD |
| Product type |
VWF/FVIII concentrate |
Recombinant VWF |
| Main commercial advantage |
Established combined replacement product |
No human plasma-derived VWF |
| Main limitation |
Plasma-pool and supply exposure |
Separate FVIII management may be required |
The comparison is clinically important. Humate-P can provide VWF and FVIII in one product, whereas recombinant VWF can reduce reliance on plasma-derived material but may require separate factor VIII in selected patients.
What is the current clinical-trial status of Humate-P?
Humate-P has a mature clinical profile rather than an active late-stage development program. Its regulatory evidence comes from historical clinical studies, postmarketing experience and long-term use in VWD and hemophilia A.
As of June 2024, public ClinicalTrials.gov records did not identify a new pivotal Humate-P trial intended to expand the product into a major new indication. The current evidence base is therefore defined by:
- FDA-approved indication studies.
- Perioperative and acute-bleeding experience.
- Published observational studies in VWD.
- Postmarketing pharmacovigilance.
- Real-world hospital and hemophilia-treatment-center use.
What clinical evidence supports Humate-P in von Willebrand disease?
The FDA prescribing information reports clinical evaluation in patients with VWD, including treatment of bleeding and surgical prophylaxis. The product is used when desmopressin is ineffective, contraindicated or insufficient, and when replacement therapy is required for major bleeding or surgery (CSL Behring, 2023).
Clinical management generally requires laboratory monitoring because the product contains both VWF and FVIII. Repeated dosing can increase FVIII exposure, creating a potential thrombosis concern in patients with additional risk factors.
What clinical evidence supports Humate-P in hemophilia A?
Humate-P is approved for on-demand treatment and control of bleeding and for perioperative management in adults with hemophilia A. Its commercial position in hemophilia is weaker than in VWD because the broader hemophilia A market has shifted toward recombinant factor VIII, extended-half-life products, emicizumab and gene therapy approaches.
Humate-P is more likely to be used in specific hospital, surgical or patient circumstances than as the default long-term hemophilia A replacement product.
What is the FDA regulatory status of Humate-P?
Humate-P is an FDA-licensed plasma-derived biologic manufactured by CSL Behring. The FDA label identifies it as a human plasma-derived VWF/FVIII concentrate and includes boxed and prominent warnings relating to thromboembolic events, hypersensitivity, inhibitor development and infectious-agent transmission risk (U.S. Food and Drug Administration, 2023).
Does Humate-P have FDA exclusivity remaining?
No meaningful new-product regulatory exclusivity period remains. Humate-P has been marketed for decades, and any original orphan-drug or biologic exclusivity period has expired.
The product can still benefit from regulatory barriers associated with:
- Manufacturing validation.
- Plasma collection and donor screening.
- Viral inactivation and removal processes.
- Lot release requirements.
- Clinical familiarity.
- Hospital formulary status.
- Supply reliability.
These barriers are commercially important even when formal exclusivity has ended.
What is the Orange Book status of Humate-P?
Humate-P is not expected to have a conventional Orange Book patent-and-exclusivity listing comparable to an approved small-molecule tablet. It is a biologic regulated through a biologics license rather than a standard new drug application.
Patent information for biologics is generally addressed through the Purple Book and the Biologics Price Competition and Innovation Act framework. However, Humate-P’s age means that its core product protection is not principally dependent on an active composition-of-matter patent.
What patents protect Humate-P?
Publicly available product information does not indicate a currently decisive, unexpired core patent blocking competing VWF/FVIII concentrates. Humate-P’s practical protection is based more on manufacturing know-how, plasma sourcing, quality systems and regulatory history than on a single enforceable product patent.
Are there formulation patents for Humate-P?
Potentially relevant intellectual property could cover stabilization, purification, viral inactivation, packaging or manufacturing processes. Those rights are distinct from a patent on Humate-P’s active biologic composition.
For commercial diligence, the relevant questions are:
- Whether any process patent remains unexpired in the target jurisdiction.
- Whether the patent is owned by CSL Behring or a predecessor entity.
- Whether the claims cover the marketed process or only a narrower manufacturing step.
- Whether a competitor can design around the process.
- Whether regulatory comparability, rather than patent infringement, is the actual entry barrier.
Are there Paragraph IV challenges to Humate-P?
A conventional Paragraph IV challenge is not the expected pathway for Humate-P because Paragraph IV litigation is associated with generic drug applications under the Hatch-Waxman Act. A competing biologic would more likely proceed through a biologics license application, a biosimilar application under Section 351(k), or a separate biologics pathway.
No major public Paragraph IV litigation program targeting Humate-P was identified through June 2024.
Can a biosimilar compete with Humate-P?
A competing product could theoretically seek approval under the biosimilar framework if it satisfies the statutory and scientific requirements. Plasma-derived VWF/FVIII products are technically difficult to characterize because they contain complex protein populations, multimer distributions and product-specific biological activity.
The commercial risk is therefore different from that for a simple generic tablet. A potential competitor would need to establish:
- Analytical similarity.
- Functional equivalence.
- Manufacturing consistency.
- Viral safety.
- Clinical or pharmacologic support.
- A reliable plasma or recombinant manufacturing platform.
The likely competitive threat is not a near-term automatic substitution wave. It is gradual displacement by established alternatives, including recombinant VWF and other licensed plasma-derived concentrates.
Which companies compete with Humate-P?
CSL Behring
CSL Behring controls Humate-P and has a broad bleeding-disorders portfolio. Its advantages include global plasma infrastructure, specialty distribution, hemophilia-treatment-center relationships and experience managing complex biologic supply chains.
Takeda
Takeda markets Vonvendi, a recombinant VWF product. Vonvendi is the most direct technology-based alternative for VWD patients and clinicians seeking a non-plasma-derived VWF product.
Octapharma
Octapharma markets Wilate, a plasma-derived VWF/FVIII concentrate in multiple jurisdictions. Availability and labeling differ by country, but Wilate is a direct competitor in the VWD replacement market.
Grifols and other plasma-product manufacturers
Grifols and other manufacturers compete in plasma-derived coagulation factor products, including VWF-containing concentrates and factor VIII products. Competition depends on country-specific approvals, reimbursement and supply availability.
Hemophilia A alternatives
For hemophilia A, Humate-P competes with recombinant and extended-half-life factor VIII products, emicizumab and, in selected markets, gene-therapy approaches. These products reduce the role of a combined VWF/FVIII concentrate in routine hemophilia prophylaxis.
How large is the Humate-P market?
CSL Behring does not separately disclose Humate-P revenue in its public financial reporting. The product is reported within broader specialty pharmaceutical or plasma-derived product categories. A precise global Humate-P revenue figure therefore cannot be calculated from company filings alone.
The addressable market has two distinct components:
| Market segment |
Humate-P position |
Direction |
| VWD acute bleeding |
Established replacement option |
Stable to growing with diagnosis |
| VWD surgery |
Strong clinical utility |
Stable |
| Hemophilia A on-demand use |
Secondary option |
Declining relative share |
| Hemophilia A routine prophylaxis |
Limited role |
Structurally pressured |
| Plasma-derived factor market |
Relevant participant |
Mature |
| Recombinant VWF market |
Competitive alternative |
Expanding |
VWD is underdiagnosed, and broader testing can increase the treated population. The product can benefit from diagnosis growth even while losing share to recombinant VWF in selected settings.
What is the Humate-P market projection through 2030?
The most defensible projection is a mature-product scenario rather than a high-growth forecast.
Base case
Humate-P revenue remains broadly stable to modestly lower through 2030. VWD surgical and acute-bleeding demand offsets declining hemophilia A use and substitution by Vonvendi or other newer therapies.
Upside case
Revenue is supported by:
- Increased VWD diagnosis.
- Continued use in emergency and surgical care.
- Product shortages affecting alternatives.
- Strong hospital contracts.
- Expanded access in emerging markets.
- Physician preference for a combined VWF/FVIII product.
Downside case
Revenue declines faster if:
- Recombinant VWF adoption expands.
- Plasma-derived products face supply constraints.
- Hospitals consolidate purchasing.
- Hemophilia A shifts further to non-factor therapies.
- A competing VWF/FVIII concentrate gains broad approval.
- Safety or manufacturing events affect confidence in plasma-derived products.
A reasonable strategic assumption is that Humate-P is a cash-generating mature biologic with low single-digit market growth exposure but a declining share risk in hemophilia A. Its strongest long-term position is VWD replacement, particularly perioperative and acute bleeding treatment.
What generic or biosimilar launch risks exist for Humate-P?
The near-term risk is more likely to come from product substitution than from a conventional generic launch.
Highest-risk areas
- Recombinant VWF adoption in VWD.
- Hospital formulary conversion.
- Alternative plasma-derived VWF/FVIII products.
- Supply-driven switching.
- Lower-cost tenders outside the United States.
- New therapies reducing factor use in hemophilia A.
Lower-risk areas
- Immediate substitution by a traditional generic.
- Automatic pharmacy substitution.
- A rapid loss of all VWD volume.
- Direct erosion from oral small-molecule therapies.
The product’s complex biologic composition and clinical history make automatic substitution unlikely. Physician and institution-level decisions will remain important.
What manufacturing and geographic barriers protect Humate-P?
Humate-P benefits from barriers that are difficult for new entrants to replicate:
- Access to qualified human plasma.
- Large-scale fractionation.
- Donor screening and testing.
- Viral inactivation and removal.
- Batch consistency.
- Cold-chain distribution.
- Regulatory inspection history.
- Hemophilia-center familiarity.
- Emergency inventory requirements.
Geographic protection is uneven. The product’s regulatory position, reimbursement and availability vary by jurisdiction. In the United States, CSL Behring has an established commercial and regulatory infrastructure. In Europe and other markets, Wilate and other VWF products may have stronger local positions.
How strong is the Humate-P commercial and patent estate?
Humate-P has a strong commercial franchise but a limited classic patent moat.
| Factor |
Assessment |
| Clinical familiarity |
Strong |
| FDA approval breadth |
Strong in VWD; narrower in hemophilia A |
| Core patent exclusivity |
Mature or expired |
| Manufacturing barrier |
Strong |
| Plasma supply barrier |
Strong |
| Biosimilar complexity |
Moderate to strong |
| Recombinant VWF threat |
Moderate and increasing |
| Hemophilia A growth prospects |
Weak |
| VWD durability |
Moderate to strong |
| Litigation exposure |
No major public Paragraph IV threat identified |
The commercial asset is more defensible than the patent estate. CSL Behring’s main advantages are manufacturing scale, clinical use history, distribution and supply management.
Key Takeaways
- Humate-P is a mature plasma-derived VWF/FVIII biologic marketed by CSL Behring.
- Its primary long-term value is in VWD bleeding control and perioperative management.
- The product has a secondary and declining role in routine hemophilia A treatment.
- No new pivotal Humate-P clinical program was publicly driving label expansion through June 2024.
- Conventional Paragraph IV litigation is not the expected competitive pathway.
- No decisive unexpired core patent barrier is apparent from public product information.
- Manufacturing, plasma supply, regulatory compliance and clinical familiarity are more important than patent exclusivity.
- Vonvendi is the most important technology-based competitor in VWD.
- Humate-P revenue is not separately disclosed by CSL Behring.
- The base-case outlook through 2030 is stable to modest decline, with VWD demand offsetting hemophilia-related erosion.
FAQs
Is Humate-P still FDA approved?
Yes. Humate-P remains FDA approved for specified VWD indications and for on-demand and perioperative treatment of bleeding in adults with hemophilia A.
Is Humate-P a recombinant biologic?
No. Humate-P is derived from pooled human plasma. Vonvendi is the principal recombinant VWF comparator.
Can Humate-P be used for von Willebrand disease surgery?
Yes. The FDA label includes perioperative management of bleeding in adults and pediatric patients with VWD.
Does Humate-P have a biosimilar?
No widely established FDA-approved biosimilar to Humate-P was identified through June 2024. A future competitor would face substantial analytical, manufacturing and regulatory requirements.
What is the largest commercial threat to Humate-P?
The largest threat is gradual substitution by recombinant VWF and other VWF-containing products, combined with reduced factor VIII demand in hemophilia A because of extended-half-life factors, emicizumab and other newer therapies.
References
-
CSL Behring. (2023). Humate-P prescribing information. U.S. Food and Drug Administration.
-
U.S. Food and Drug Administration. (2023). Humate-P: Package insert and biologics licensing information. https://www.fda.gov
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
-
ClinicalTrials.gov. (2024). Search results for Humate-P and von Willebrand disease clinical studies. U.S. National Library of Medicine. https://clinicaltrials.gov
-
CSL Limited. (2023). Annual report 2023. https://www.csl.com
-
Takeda Pharmaceuticals. (2023). Vonvendi prescribing information. U.S. Food and Drug Administration.
